Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I topical CyPep-1 in adults with cutaneous common warts
NL-OMON48409Phase 1Completed
- Sponsor
- Cytovation
- Start
- Feb 2019
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in verruca and human papillomavirus infection comparing CyPep-1 topical formulation with Vehicle placebo (2 arms). Primary endpoints: Safety and tolerability on healthy skin, Safety and tolerability on cutaneous warts and 12 more. Started Feb 2019; status: completed.
02
Drugs
cypep-1
03
Conditions
verrucahuman papillomavirus infection
Beyond the preview
Go deeper on NL-OMON48409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48409.